MB12 vs Nivolumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

MB12

Developed by Laboratorio Elea Phoenix S.A. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05668650 · Phase 3 · status unknown

This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.

No aligned efficacy figure on record for this race.

Nivolumab

Marketed by Bristol-Myers Squibb and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT01673867 · Phase 3 · completed

This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT02955290 (registry estimate)

Reported efficacy

Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)

Result source: NCT01673867

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMB12Nivolumab
PFS, median—Trial running · NCT0668736912.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results
OS, median—Trial running · NCT0668736912.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results
ORR—Trial running · NCT0668736961.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059
Duration of response, median—Trial running · NCT0668736911 vs 7+4 vs placebon 275NCT03117049
12 other results

PFS, median

MB12
—Trial running · NCT06687369
Nivolumab
12.1 vs 8.1+4 vs placebon 275NCT03117049
22 other results

OS, median

MB12
—Trial running · NCT06687369
Nivolumab
12.2 vs 9.4vs Docetaxeln 292NCT01673867
20 other results

ORR

MB12
—Trial running · NCT06687369
Nivolumab
61.5% vs 50.5%+11 vs placebon 275NCT03117049
19 other results
  • 19.5% vs 12.8% n 292 · Phase 3 · secondary NCT01673867
  • 20% vs 8.8% n 135 · Phase 3 · secondary NCT01642004
  • 36.4% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 27.5% vs 29.7% n 396 · Phase 3 · secondary NCT02477826
  • 26.2% vs 29.7% n 187 · Phase 3 · secondary NCT02477826
  • 37.9% vs 29.7% n 177 · Phase 3 · secondary NCT02477826
  • 52.3% vs 29.7% n 377 · Phase 3 · secondary NCT02477826
  • 38.1% vs 29.7% n 126 · Phase 3 · secondary NCT02477826
  • 67.6% vs 64.5% n 287 · Phase 3 · secondary NCT04026412
  • 72.2% vs 64.5% n 320 · Phase 3 · secondary NCT04026412
  • 61.3% vs 57.9% n 287 · Phase 3 · secondary NCT04026412
  • 63.1% vs 57.9% n 320 · Phase 3 · secondary NCT04026412
  • 26.1% vs 33.5% n 211 · Phase 3 · secondary NCT02041533
  • 50.6% vs 43% wk 64 · n 158 · Phase 2 · primary NCT04623775
  • 14.5% 3 mg/kg · n 117 · Phase 2 · primary NCT01721759
  • 17.1% 480mg Q4W · n 129 · Phase 2 · secondary NCT03090737
  • 15.4% 3 mg/kg · n 117 · Phase 2 · secondary NCT01721759
  • 32.3% n 288 · Phase 2 · secondary NCT02659059
  • 47.2% n 36 · Phase 2 · secondary NCT02659059

Duration of response, median

MB12
—Trial running · NCT06687369
Nivolumab
11 vs 7+4 vs placebon 275NCT03117049
12 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MB12: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. MB12: 0 of 4 rows · Nivolumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricNivolumab
Dropout rate
—480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
1.7%360 mg
NCT02998528 · Phase 3 · combination
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
66%
NCT03444766 · Phase 4 · registry result, not featured evidence
64.1%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
73.1%
NCT03117049 · Phase 3 · registry result, not featured evidence
0.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
2.1%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
2.7%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT02041533 · Phase 3 · registry result, not featured evidence
1.1%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
1.6%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
n/a: no completion milestoneNivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
88.2%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
90.6%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
2.5%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
8.7%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
23.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
0%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
37.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
87.2%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
88.9%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
—3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.3%Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.7%Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.6%360 mg
NCT02998528 · Phase 3 · combination
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
6%
NCT03444766 · Phase 4 · registry result, not featured evidence
—Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
—
NCT03117049 · Phase 3 · registry result, not featured evidence
—
NCT02613507 · Phase 3 · registry result, not featured evidence
0.7%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
0%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
—
NCT02041533 · Phase 3 · registry result, not featured evidence
—480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
—Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
11.8%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
5%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
—Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
—Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
0%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
4.8%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
0%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
—Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
13.8%
NCT02350764 · Phase 2 · registry result, not featured evidence
—600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
5.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
11.1%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
11.1%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
9.4%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Serious AEs
33.3%480 mga
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 43 more results
59.9%3 mg/kg
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.7%480 mg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
64.9%3 mg/kg
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—Nivolumab
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
30.1%360 mg
NCT02998528 · Phase 3 · combination
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · combination
30%
NCT03444766 · Phase 4 · registry result, not featured evidence
63.8%Arm A:Nivo + CCRT/Nivo + Ipi
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.9%Arm B: Nivo + CCRT/Nivo
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT03117049 · Phase 3 · registry result, not featured evidence
54.3%
NCT02613507 · Phase 3 · registry result, not featured evidence
54.6%Arm A: Nivolumab Plus Platinum-dou
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
64.8%Arm B: Nivolumab Plus Ipilimumab
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
73%
NCT02041533 · Phase 3 · registry result, not featured evidence
34.8%480 mg every 4 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
39.4%240 mg every 2 weeks
NCT02713867 · Phase 3 · registry result, not featured evidence
44.9%Cohort A: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
41.6%Cohort B: Nivolumab Monotherapy (P
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
—Nivolumab Monotherapy (Not Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
60.9%Nivolumab Monotherapy (Pre-Randomi
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
70.6%HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
41%Non-HBV Participants
NCT03195491 · Phase 3 · registry result, not featured evidence
59.7%Part 1: Treatment A
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
17.4%Arm A - Nivolumab
NCT03158129 · Phase 2 · registry result, not featured evidence
14.3%Arm B - Nivolumab + Ipilimumab
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
31.8%Arm C - Nivolumab + Chemotherapy
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
13.6%Arm D - Nivolumab + Ipilimumab + C
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
37.5%Pixatimod (PG545) + Nivolumab + Cy
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
20%Pixatimod (PG545) + Nivolumab - Co
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
100%600 mg
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
43.4%480mg Q4W
NCT03090737 · Phase 2 · registry result, not featured evidence
59.4%Nivolumab+Ipilimumab
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
72.2%Nivolumab+Ipilimumab+Chemotherapy
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
75.2%3 mg/kg
NCT01721759 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
480 mga
cough 33.3%
arthralgia 20%
rash 20%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 40 more results
3 mg/kg
fatigue 33.4%
decreased appetite 31.7%
cough 28.9%
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
480 mg
nausea 33.3%
vomiting 33.3%
abdominal pain 16.7%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3 mg/kg
dyspnoea 35.9%
cough 34.4%
fatigue 32.1%
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
360 mg
nausea 41.5%
constipation 35.8%
anaemia 35.2%
NCT02998528 · Phase 3 · combination
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · combination
cough 24%
pyrexia 21%
vomiting 17%
NCT03444766 · Phase 4 · registry result, not featured evidence
anaemia 44%
nausea 34.8%
constipation 29.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
anaemia 41.5%
nausea 32.7%
cough 26.1%
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
constipation 54.9% (placebo 48.7%)
alopecia 52.4% (placebo 54.5%)
peripheral sensory neuropathy 44.3% (placebo 42.2%)
NCT03117049 · Phase 3 · registry result, not featured evidence
anaemia 34.7%
decreased appetite 31.5%
fatigue 31.2%
NCT02613507 · Phase 3 · registry result, not featured evidence
anaemia 46.8%
nausea 44.7%
constipation 36.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
constipation 29.6%
pruritus 25.4%
diarrhoea 23.9%
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
fatigue 40.4%
decreased appetite 34.1%
nausea 32.2%
NCT02041533 · Phase 3 · registry result, not featured evidence
480 mg every 4 weeks
diarrhoea 16.9%
pruritus 16.9%
fatigue 15.7%
NCT02713867 · Phase 3 · registry result, not featured evidence
240 mg every 2 weeks
pruritus 23.3%
diarrhoea 22.8%
fatigue 22.2%
NCT02713867 · Phase 3 · registry result, not featured evidence
diarrhoea 28.3%
arthralgia 23.6%
upper respiratory tract infection 22%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
cough 17.6%
weight decreased 16%
arthralgia 14.4%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
fatigue 36.1%
dyspnoea 23.7%
nausea 23.2%
NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy
anaemia 41.2%
cough 41.2%
hyponatraemia 35.3%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 40.5%
decreased appetite 24.5%
cough 22.2%
NCT03195491 · Phase 3 · registry result, not featured evidence
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
fatigue 34.8%
anemia 30.4%
rash acneiform 26.1%
NCT03158129 · Phase 2 · registry result, not featured evidence
rash acneiform 61.9%
cough 38.1%
fatigue 38.1%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
nausea 81.8%
fatigue 72.7%
anemia 54.5%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 50%
diarrhea 40.9%
nausea 40.9%
NCT03158129 · Phase 2 · registry result, not featured evidence · combination
anemia 62.5%
fatigue 50%
hyponatremia 50%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
activated partial thromboplastin time prolonged 80%
hypertriglyceridemia 60%
hyponatremia 60%
NCT05061017 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 100%
hypoalbuminemia 93.1%
anemia 75.9%
NCT02350764 · Phase 2 · registry result, not featured evidence
600 mg
blood alkaline phosphatase increased 100%
blood lactate dehydrogenase increased 100%
bronchitis 100%
NCT05005273 · Phase 2 · registry result, not featured evidence · combination
480mg Q4W
anaemia 28.7%
blood alkaline phosphatase increased 24.8%
rash 20.2%
NCT03090737 · Phase 2 · registry result, not featured evidence
fatigue 55.2%
diarrhoea 38.5%
nausea 38.2%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.6%
pruritus 47.2%
nausea 44.4%
NCT02659059 · Phase 2 · registry result, not featured evidence · combination
3 mg/kg
fatigue 53%
decreased appetite 39.3%
dyspnoea 38.5%
NCT01721759 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Nivolumab

Overall Survival NA vs 73.72 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 18 more results
12.19 vs 9.36 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.21 vs 9.49 Docetaxel months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.23 vs 6.01 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
17.12 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.7 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3
17.45 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
15.21 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
18.27 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
20.99 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · combination
34.6 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
39.49 vs 39.79 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
25.4 vs 24.7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
11.99 vs 9.63 Docetaxel months
NCT02613507 · Phase 3 · registry result, not featured evidence
19.35 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
17.12 vs 15.9 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
14.36 vs 13.21 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
13.73 vs 13.8 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
ORR 19.5% (n=292) vs 12.8% (n=290) Docetaxel
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
20% (n=135) vs 8.8% (n=137) Docetaxel
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
36.4% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
27.5% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3
26.2% (n=187) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
37.9% (n=177) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
52.3% (n=377) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
38.1% (n=126) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · combination
67.6% (n=287) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
72.2% (n=320) vs 64.5% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.3% (n=287) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
63.1% (n=320) vs 57.9% (n=318) Durva
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=275) vs 50.5% (n=275) placebo
NCT03117049 · Phase 3 · registry result, not featured evidence
26.1% (n=211) vs 33.5% (n=212) Investigator Choice of Chemotherapy
NCT02041533 · Phase 3 · registry result, not featured evidence
50.6% (n=158) vs 43% (n=151) Nivolumab + Chemotherapy @ 64wk
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
Time to Response 2.1 vs 2.73 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 5 more results
2.23 vs 2.09 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
2.92 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.92 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.96 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
2.92 vs 2.89 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 17.15 vs 5.55 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 9 more results
24.51 vs 8.41 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
25.76 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
31.84 vs 25.17 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
22.83 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
33.18 vs 27.93 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
11 vs 7 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
6.67 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
50.04 vs 5.55 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
8.41 vs 7.1 Nivolumab + Chemotherapy months
NCT04623775 · Phase 2 · registry result, not featured evidence · combination
PFS 2.33 vs 4.44 Docetaxel months
time to event · months
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
3.48 vs 2.83 Docetaxel months
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
5.06 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
4.17 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3
4.9 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.55 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
8.34 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
5.78 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · combination
16.69 vs 15.64 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.38 vs 15.67 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
16.82 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
17.71 vs 16.53 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
12.1 vs 8.1 placebo months
NCT03117049 · Phase 3 · registry result, not featured evidence
5.59 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
1.54 vs 5.45 Platinum Doublet Chemotherapy months
NCT02864251 · Phase 3 · registry result, not featured evidence · combination
4.21 vs 5.88 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
4.21 vs 5.82 Investigator Choice of Chemotherapy months
NCT02041533 · Phase 3 · registry result, not featured evidence
Disease-related Symptom Improvement 17.8% (n=292) vs 19.7% (n=290) Docetaxel @ 12wk
responder rate · % of participants
NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 2 more results
18.5% (n=135) vs 21.2% (n=137) Docetaxel @ 12wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
35.4% (n=271) vs 33.7% (n=270) Investigator Choice of Chemotherapy @ 12wk
NCT02041533 · Phase 3 · registry result, not featured evidence
Overall Survival 63.7% (n=135) vs 50.7% (n=137) Docetaxel @ 26wk
absolute value · percentage points
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 11 more results
42.2% (n=135) vs 24.3% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.5% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
63.7% (n=135) vs 50.4% (n=137) Docetaxel @ 26wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
42.2% (n=135) vs 24.1% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
28.1% (n=135) vs 12.4% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
23% (n=135) vs 8% (n=137) Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.6% (n=135) vs 5.8% (n=137) Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1% (n=135) vs 4.4% (n=137) Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
12.3% (n=135) vs 3.6% (n=137) Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11.4% (n=135) vs 2.7% (n=137) Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
9.6% (n=135) vs 0% (n=137) Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
PFS 38.4% (n=135) vs 22.6% (n=137) Docetaxel @ 26wk
responder rate · % of participants
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 8 more results
21% (n=135) vs 7.2% (n=137) Docetaxel @ 52wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.87% (n=135) vs 1.8% (n=137) Docetaxel @ 78wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
14.8% (n=135) vs NA Docetaxel @ 104wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
11% (n=135) vs NA Docetaxel @ 156wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 208wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
8.9% (n=135) vs NA Docetaxel @ 260wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
7.6% (n=135) vs NA Docetaxel @ 312wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
6.1% (n=135) vs NA Docetaxel @ 364wk
NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Event-Free Survival 31.57 vs 20.8 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 1 more result
59.6 vs 21.06 Platinum Doublet Chemo months360 mg
NCT02998528 · Phase 3 · combination
Pathologic Complete 24% (n=179) vs 2.2% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 43 Participants as posted
Major Pathologic 36.9% (n=179) vs 8.9% (n=179) Platinum Doublet Chemo360 mg
responder rate · % of participants
NCT02998528 · Phase 3 · combination · converted to % from 66 Participants as posted
Time to Death or Distant Metastasis 64.66 vs 36.76 Platinum Doublet Chemo months360 mg
time to event · months
NCT02998528 · Phase 3 · combination
show 2 more results
30.65 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination
36.14 vs 30.36 Durva months
NCT04026412 · Phase 3 · registry result, not featured evidence · combination

+ 41 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MB12's landscape · Nivolumab's landscape